G Medical Innovations IPO Presentation Deck

Investment Highlights • FDA cleared tele-health devices with CPT code reimbursement approval at more than 150 leading health insurance providers in the US. • CMS approved independent diagnostic testing facilities. • Commercial agreements in place for the marketing, sale and distribution of our Prizma suite of devices. ● • $21 million in revenue from sales of our devices & monitoring services in the last 4 and a half years. ● 7 granted patents covering key aspects of our devices. 31 at-home testing kits expected to be available in Q3 2023 online and in US retail stores. CHER DATA UMOROSING SUMICES 22

View entire presentation